DexCom, Inc. - DXCM STOCK NEWS

DexCom, Inc. (NASDAQ:DXCM) announced its plans to release financial results for the fourth quarter and full year 2022 on February 9, 2023, post market close. The management will discuss the results in a conference call at 4:30 p.m. ET on the same day, which will also be available via webcast. This financial report is crucial for investors and stakeholders to gauge the company's performance in the diabetes care technology sector.

Dexcom, Inc. (NASDAQ: DXCM) announced an expansion of coverage for its Dexcom G6 real-time continuous glucose monitoring (rtCGM) system under the Non-Insured Health Benefits (NIHB) program. This change allows all clients living with type 1 diabetes, beyond the existing restriction for ages 2 to 19, to receive coverage. The initiative aims to improve health outcomes for Indigenous communities, who are disproportionately affected by diabetes, by providing greater access to essential healthcare technology. The Dexcom G6 system aids in better glucose control and reduces the risk of diabetes-related complications.

DexCom, Inc. (NASDAQ: DXCM) has appointed Teri Lawver as the chief commercial officer, a newly created role responsible for global sales, marketing, and customer experience. Ms. Lawver brings over 20 years of leadership experience from Johnson & Johnson, where she successfully grew the immunology business from $11 billion to $16 billion. CEO Kevin Sayer praised her ability to drive growth in the healthcare sector. Ms. Lawver aims to leverage Dexcom's market opportunities and technology to expand the reach of continuous glucose monitoring solutions.

DexCom, Inc. (NASDAQ: DXCM) expects preliminary revenue of at least $815 million for Q4 2022, a 17% increase over the prior year. For the full fiscal year 2022, revenue is anticipated to be around $2.91 billion, up 19%. Looking ahead to 2023, DexCom projects total revenue of $3.35 billion to $3.49 billion, reflecting expected growth of 15% to 20%. The company also aims for a Non-GAAP gross profit margin of 62-63% and an operating margin of approximately 16.5%.

DexCom, Inc. (NASDAQ:DXCM) announced that CEO Kevin Sayer will present at the 41st annual J.P. Morgan Healthcare Conference on January 9, 2023, starting at 2:15 PM EST. The presentation will be webcast live and made available for later viewing on the Dexcom Investor Relations website.

DexCom focuses on diabetes management through its innovative continuous glucose monitoring (CGM) systems, serving users globally from its headquarters in San Diego, California.

Dexcom, Inc. (NASDAQ: DXCM) has launched a new Digital Diabetes Care Program in partnership with Green Shield and The Health Depot. This initiative will provide Green Shield plan members access to the Dexcom G6 real-time continuous glucose monitoring (rtCGM) system along with virtual diabetes management support. Benefits include automated product shipments, preferred pricing, direct billing, and co-payment assistance for Dexcom supplies. The program aims to enhance diabetes management and improve health outcomes by providing personalized support and clinical consultations.

Dexcom G7 has received FDA clearance for all diabetes types in individuals aged two and older. This next-generation continuous glucose monitoring (CGM) system boasts an overall MARD of 8.2%, making it the most accurate FDA-cleared CGM. With a 60% smaller, all-in-one wearable design, it offers a 30-minute sensor warmup and a suite of features including real-time connectivity with wearables and an upgraded mobile app. Furthermore, Dexcom's G7 is the number one covered CGM, with many users incurring low out-of-pocket costs.

Dexcom, Inc. (NASDAQ: DXCM) announces its participation in the Truckers’ Health Adaptive Technology (T.H.A.T.) project to enhance health outcomes for professional truck drivers during National Diabetes Awareness Month. This initiative utilizes real-time continuous glucose monitoring via Dexcom G6 systems, integrating health data to provide personalized virtual care. The T.H.A.T. project will track health metrics of 200 truck drivers and aims to address their higher diabetes risk. This innovative model may be expanded to other high-risk workforces in Canada.

DexCom, Inc. (NASDAQ:DXCM) announced that Matt Dolan, Executive Vice President of Strategy, Corporate Development, and DexCom Labs, will present at the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 8:30 am (EST). The presentation will provide updates about the company and its innovative continuous glucose monitoring systems aimed at improving diabetes management.

Links to the live webcast and archived presentation will be available on the DexCom Investor Relations website.